Kaoru Kobayashi

Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography.

Using positron emission tomography (PET) and [11C]N-methylspiperone (NMSP), we examined 5-HT2 receptors in the cortex of schizophrenic patients in whom we previously observed decreased prefrontal D1 receptor binding. The subjects were 10 neuroleptic-naive schizophrenic patients, 7 schizophrenic patients who were drug-free but had previously been treated with neuroleptics, and 12 normal controls. A non-significant trend towards decreased prefrontal [11C]NMSP binding was observed in the neuroleptic-treated patients, suggesting a possible effect of previous neuroleptic treatment on the alteration in cortical 5-HT2 function. However, the neuroleptic-naive patients showed no noticeable difference in cortical [11C]NMSP binding compared to controls. Our results do not rule out the role of 5-HT2 function as a crucial site of therapeutic activity of schizophrenia, but they do suggest that cortical 5-HT2 receptors might not be primarily involved in the pathophysiology of schizophrenia.

Age-related changes in human muscarinic acetylcholine receptors measured by positron emission tomography

The effects of age on the binding parameters of [11C]N- methyl-4-piperidylbenzilate ([11C]NMPB), a specific muscarinic cholinergic receptor ligand, were studied. Eighteen healthy male volunteers (18-75 years old) participated. Regional radioactivity in the brain was followed for 60 min by positron emission tomography (PET). Uptake of [11C]NMPB continuously increased in all brain areas with the exception of the cerebellum. For the quantification of receptor binding, a compartment model, in which radioactivity in the cerebellum was used as an input function, was used. The binding parameter, K3, of muscarinic acetylcholine receptors in eight brain regions (pons, hippocampus, frontal cortex, striatum, temporal cortex, thalamus, occipital cortex, parietal cortex) showed an age-related decrease of about 45% over the age range.

Difference in in vivo receptor binding between [3 H]N-methylspiperone and [3 H]raclopride in reserpine-treated mouse brain

The in vivo binding of [3 H]N-methylspiperone (NMSP) and [3 H]raclopride was compared in mice treated with reserpine (5 mg/kg, 24 hr prior to the tracer injection). With both radioligands, selective accumulation of radioactivity in the striatum following intravenous injection was observed, whereas a relatively low accumulation and a rapid decline in radioactivity in the cerebellum was seen. Reserpine significantly decreased [3 H]NMSP binding in vivo, however it increased [3 H]raclopride binding. By compartment model analysis, it was found that the decrease in [3 H]NMSP binding was primarily due to the decrease in the association rate (K3) and the increase in [3 H]raclopride was due to the decrease in the dissociation rate (K4) in vivo. As both Kd and Bmax of dopamine D2 receptors have been reported to be unaltered by reserpine, these results suggested that some unknown factors except Kd and Bmax which influence on in vivo binding of receptors might be changed by reserpine. These results revealed that it is of importance to measure kinetics of ligand-receptor binding in vivo rather than static analysis. These two different types of radioligands can be combined to reveal functional roles of dopamine receptor in vivo, especially in the study of the human brain with positron emission tomography (PET).

No age-related changes in human benzodiazepine receptor binding measured by PET with [11C]Ro 15-4513

The effects of age on the binding of [11C]Ro 15-4513, a partial inverse agonist of the central benzodiazepine receptor, were studied. Sixteen healthy male volunteers (21-78 years old) participated. Regional radioactivity in the brain was followed for 45 min by positron emission tomography after a bolus injection of [11C]Ro 15-4513. Similar tracer kinetics were observed in both young and old subjects. For the quantification of receptor binding in vivo, a compartment model, in which radioactivity in the pons was used as an input function, was applied. There were no significant changes in the binding potentials with age (P > 0.1) in ten brain regions. These observations delineate an interesting difference between central benzodiazepine (BZ) receptors and other neurotransmitter receptors in the human brain measured by PET that have been shown to have a reduction with age.

In vivo binding of [11C]Ro15-4513 in human brain measured with PET

Ro15-4513, an azide derivative of benzodiazepine antagonist flumazenil (Ro15-1788), and Ro15-1788 were labelled with carbon 11. Sequential PET scans following injection of [11C]Ro15-4513 or [11C]Ro15-1788 into normal male healthy volunteers were measured, and kinetic analysis using pons as a reference region was performed. [11C]Ro15-4513 was highly accumulated in frontal cortex, temporal cortex, hippocampus and relatively lower accumulation in occipital cortex, whereas almost homogeneous distribution of Ro15-1788 throughout cortex area was seen. The kinetic analysis revealed that such differences of regional distribution in brain between two labelled ligands were mainly due to the regional difference of the dissociation rate constants in vivo (k4). [11C]Ro15-4513 may be a useful tool for the in vivo study of benzodiazepine receptors in human brain.

An acute effect of triazolam on muscarinic cholinergic receptor binding in the human brain measured by positron emission tomography

An acute effect of triazolam, a potent benzodiazepine agonist, on cholinergic receptor binding in the human brain was measured by PET (positron emission tomography) using [11C]N-methyl-4-piperidylbenzilate ([11C]NMPB), a potent muscarinic cholinergic receptor antagonist. Two PET scans were performed in each subject: (1) control scan; (2) after oral administration of 0.5 mg triazolam or placebo. The previously discussed amnestic effect of triazolam was measured by immediate and delayed recall of meaningful and meaningless syllables. A compartment model employing the radioactivity in the cerebellum as an input function was used for the quantification of receptor binding. The binding parameter,k3, was decreased after triazolam administration in all measured regions, whereas no change was observed after placebo treatment. The reduction compared to the control study varied from 8.6±3.7% in the temporal cortex to 16.3±6.3% in the thalamus. Triazolam administration impaired both immediate and delayed recall of syllables, whereas placebo administration had no effects. Benzodiazepine agonists are reported to decrease the cortical acetylcholine release. The decrease of acetylcholine release in the synaptic cleft might be the explanation for the decreased binding of [11C]NMPB.

The effect of benzodiazepines on the binding of [3H]SCH 23390 in vivo

The effect of flunitrazepam upon the binding of [3H]SCH 23390 in vivo was investigated. Acute treatment with flunitrazepam decreased the binding of [3H]SCH 23390 in the striatum in a dose-dependent manner. The time course of radioactivity in the striatum, cerebral cortex and cerebellum in controls and flunitrazepam (1 mg/kg)-treated mice was measured after intravenous injection of [3H]SCH 23390. The binding kinetics were calculated, using the cerebellum as a reference region for the estimation of the amount of free ligand in the brain. Flunitrazepam significantly decreased the input rate constant to the receptor compartment and the dissociation rate constant in vivo. An in vivo displacement study, using carrier SCH 23390, also showed significant reduction in the dissociation rate constant of [3H]SCH 23390 in vivo. The drug Ro 15-1788 reversed the effect of flunitrazepam, suggesting that this reduction in binding of [3H]SCH 23390 was mediated by benzodiazepine receptors. To evaluate the relationship between the reduction in binding of [3H]SCH 23390 in vivo and in vivo occupancy of benzodiazepine receptors, in vivo occupancy of benzodiazepine receptors was measured using [3H]Ro 15-1788. A non-linear relationship was found between the reduction in dopamine D1 receptor binding in vivo and the occupancy of benzodiazepine receptors in vivo, indicating that benzodiazepines exerted the maximum change in dopamine receptor binding at a low fractional occupancy of receptors.

Swim stress alters in vivo binding of [3H]N-methylspiperone

The effect of swim stress on the in vivo binding of [3H]N-methylspiperone in the striatum of the mouse was investigated. Mice were forced to swim for 5 min at 18 degrees C and the time course of radioactivity in the striatum and cerebellum, following intravenous injection of [3H]N-methylspiperone was measured. The ratio of radioactivity in the striatum to that in the cerebellum was plotted as a function of time for the estimation of in vivo binding to dopamine D2 receptors. Immediately after the swim stress, a significant decrease in binding to D2 receptors in vivo was observed. Neither the KD nor Bmax determined by in vitro binding were altered by swim stress. The time course of the changes in binding, within a 24 hr period, following the swim stress was also studied and a rapid reversal of binding, within 1 hr after the swim stress was observed. In vivo binding of [3H]N-methylspiperone in the cerebral cortex, which appeared to involve serotonin receptors, as well as D2 receptors, was not significantly altered by the swim stress. A saturation study of in vivo binding indicated that the decreases in binding to D2 receptors, due to swim stress, were primarily caused by changes in the apparent affinity rather than in the number of binding sites available in vivo. These results support the hypothesis that micro-environmental factors, including the diffusion barrier to the synapse, might be altered by swim stress.

Effect of 6R-Tetrahydrobiopterin on the Central Muscarinic Cholinergic Receptor as Evaluated by Positron Emission Tomography Studies Using Rhesus Monkey

Our recent microdialysis studies demonstrated the effect of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (R-THBP) on the acethylcholinergic system as well as dopaminergic, serotonergic, and glutamatergic systems in the rat brain1–3. Enhancement of acetylcholine release by R-THBP occurs via activation of serotonergic system3. More recently, by using positron emission tomography (PET) with 3,4-dihydroxy-L-[s-11C ] phenylalanine (DOPA), we demonstrated the enhancement of DOPA turnover in vivo and maybe dopamine release in vivo by peripheral administration of R-THBP4. Here, we intend to show the effect of R-THBP on the muscarinic cholinergic receptor in unanesthetized rhesus monkeys.